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Letters to the Editor
Hibernating Myocardium, Apoptosis,
and a Simple Mathematical Task
We read with extreme interest the recent report by Elsasser et al.
(1). Their study reliably shows that both apoptotic and autophagic
cell death occur in hibernating myocardium and may be responsi-
ble for progressive clinical deterioration and lack of functional
recovery.
However, we are afraid the investigators may have made an
inaccurate estimate of apoptotic cell death rate. The researchers
indeed report an incidence of apoptosis of 0.002% (i.e., 1 of 50,000
cells). These data would suggest that at least 50,000 cells were
counted per patient in order to ascertain whether at least one was
apoptotic. But the investigators fail to clarify this issue thoroughly.
This point is particularly relevant when considering the electron
microscopy data. Considering the specific limitations of electron
microscopy we would imagine that the investigators evaluated not
more than 100 cells at electron microscopy per case. Yet assuming
100 cells examined per case and an apoptotic rate of 1 in 50,000,
the chance of randomly finding an apoptotic cell at the electron
microscope level in a single case would be 1 in 500. Accordingly,
the probabilty of 3 positive cases at electron microscopy would be
only 1 in 125 million.
In conclusion, we find the message given by Elsasser et al. (1)
extremely attractive and clinically relevant. However, we believe
that they might have underestimated the incidence of apoptotic
myocytes at confocal microscopy. We would greatly appreciate it if
the investigators could clarify these apparent inconsistencies.
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We thank Dr. Abbate and colleagues for their interest in our work
(1). The major point of our recent publication is the fact that
autophagic cell death as described previously in patients with dilated
cardiomyopathy (2) is an important mechanism for killing myocytes
in hibernating myocardium and that apoptosis seems to be of less
importance. We are fully aware of the many technical problems that
might occur when attempting a quantitative analysis of the rate of cell
death, be it apoptosis, autophagic cell death, or necrosis (3). In our
experience, electron microscopy is not a suitable method for deter-
mining the rate of cell death, which has been emphasized by others as
well (4). Therefore, we use the confocal microscope. We analyze
entire sections, and as many cells as are available from the patient’s
material; we count the total number of nucleated myocytes per patient
and we determine the number of specifically labeled cells. This
information is then statistically analyzed on the basis of individual data
from each patient and ultimately expressed as a percentage. In a final
stage, results are summarized for an entire group of patients, and
different groups are compared by employing appropriate statistical
tests. Using this procedure each patient is weighted equally, even if
there are no labeled cells present.
We read with interest Dr. Abbate and colleagues’ work on
myocardial apoptosis in patients with unfavorable left ventricular
remodeling and we noticed the unusually high rates of apoptosis
reported for both infarcted myocardium and areas remote from the
infarct (5). Unfortunately, a precise indication of the total number
of myocytes examined is lacking from the description of methods,
rendering difficult an interpretation of these results. It would have
been more convincing had Dr. Abbate and colleagues used the
same criteria in his own work that he requests from ours.
There is no doubt, however, that myocyte death is a major
contributing factor to the deterioration of cardiac function in
pathological situations in the human heart, either in postinfarction
remodeling or in hibernating myocardium.
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